Octapharma AG Clinical Trial Begins in the US and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma, one of the largest human protein products manufacturers in the world, today announced that patients diagnosed with severe hemophilia A have started treatment with the first recombinant Factor VIII derived from a human cell line (Human-cl rhFVIII). Researchers are investigating pharmacokinetics, efficacy, safety and immunogenicity of Human-cl rhFVIII for previously treated patients with severe hemophilia A.